Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.10 and traded as high as $2.56. Microbot Medical shares last traded at $2.48, with a volume of 1,134,539 shares traded.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 price target on shares of Microbot Medical in a research note on Thursday, April 10th. Wall Street Zen upgraded shares of Microbot Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 14th.
Read Our Latest Research Report on MBOT
Microbot Medical Trading Down 1.4%
The business's fifty day moving average is $2.56 and its 200 day moving average is $2.10. The firm has a market capitalization of $91.49 million, a P/E ratio of -3.87 and a beta of 1.13.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. As a group, sell-side analysts predict that Microbot Medical Inc. will post -0.71 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Microbot Medical
A number of large investors have recently made changes to their positions in MBOT. Beacon Capital Management LLC grew its position in Microbot Medical by 166.7% in the second quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock worth $40,000 after acquiring an additional 10,000 shares in the last quarter. U.S. Capital Wealth Advisors LLC bought a new stake in Microbot Medical in the second quarter valued at about $25,000. Geode Capital Management LLC increased its stake in Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares during the period. Lazari Capital Management Inc. acquired a new stake in shares of Microbot Medical during the 2nd quarter worth about $54,000. Finally, Virtu Financial LLC acquired a new stake in shares of Microbot Medical during the 1st quarter worth about $42,000. Institutional investors and hedge funds own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
